Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCLAIM: Pemetrexed vs Etoposide in Stage III NSCLC
NCT00686959Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2008
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of pemetrexed in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Eli Lilly and Company. Started Sep 2008; status: completed.
02
Drugs
pemetrexed
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT00686959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00686959.